Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07470983) titled 'A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism' on March 10.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Shandong Suncadia Medicine Co., Ltd.
Condition:
Primary Aldosteronism
Intervention:
Drug: HRS-1780 Tablets
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: March 2026
Target Sample Size: 60
Countries of Recruitment:
China
To ...